AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ECO ANIMAL HEALTH GROUP PLC

Remuneration Information Apr 29, 2022

7612_rns_2022-04-29_e986c221-586f-4df1-b0f9-aeb26d56fe8e.html

Remuneration Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 8952J

Eco Animal Health Group PLC

29 April 2022

29 April 2022

ECO Animal Health Group PLC

BLOCK LISTING RETURN

Date: 29 April 2022

Name of applicant: ECO Animal Health Group plc
Name of scheme: Executive Share Option Scheme and Unapproved Share Option Scheme
Number and class of securities originally listed and the date of admission: 1,500,000 ordinary shares of 5 pence each on 20 July 2017
Period of return: From: 1 May 2021 To: 29 April 2022
Balance of unallotted securities under scheme(s) from previous return: 393,005
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0
Less:  Number of securities issued/allotted under scheme(s) during period: 17,500
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 375,505

For further information, please contact:

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)
020 8447 8899
IFC Advisory

Graham Herring

Zach Cohen
020 3934 6630
Singer Capital Markets (Nominated Adviser & Joint Broker)

Mark Taylor

George Tzimas
020 7496 3000
Investec (Joint Broker)

Gary Clarence

Alex Penney

Carlo Spingardi

Peel Hunt LLP (Joint Broker)

Dr Christopher Golden

James Steel
020 7597 5970

020 7418 8900
Equity Developments

Hannah Crowe

Matt Evans
020 7065 2692

About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLREAELNALAAEFA

Talk to a Data Expert

Have a question? We'll get back to you promptly.